• 1
    Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3-12.
  • 2
    Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing [serial online]. PLoS One. 2011;6:e20294.
  • 3
    D'Adamo R. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol. 2011;38:S19-S29.
  • 4
    Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2011;22:1266-1272.
  • 5
    Penel N, Marreaud S, Robin YM, Hohenberger P. Angiosarcoma: state of the art and perspectives. Crit Rev Oncol Hematol. 2011;80:257-263.
  • 6
    Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26:5269-5274.
  • 7
    Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17:260-266.
  • 8
    Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133-3140.
  • 9
    Mehrabi A, Kashfi A, Fonouni H, et al. Primary malignant hepatic epithelioid hemangioendothelioma. Cancer. 2006;107:2108-2121.
  • 10
    Kitaichi M, Nagai S, Nishimura K, et al. Pulmonary epithelioid haemangioendothelioma in 21 patients, including 3 with partial spontaneous regression. Eur Respir J. 1998;12:89-96.
  • 11
    Emamaullee JA, Edgar R, Toso C, et al. Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: implications for treatment and surgical management. Liver Transplant. 2010;16:191-197.
  • 12
    Hatva E, Bohling T, Jaaskelainen J, Persico MG, Haltia M, Alitalo K. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol. 1996;148:763-775.
  • 13
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
  • 14
    Cioffi A, Italiano A, Penel N, et al. Metastatic epithelioid hemangioendothelioma (EHE): role of systemic therapy and survival [abstract]. J Clin Oncol. 2011;29S. Abstract 10079.
  • 15
    Radzikowska E, Szczepulska-Wojcik E, Chabowski M, et al. Pulmonary epithelioid hemangioendothelioma—interferon 2-alpha treatment—case report. Pneumol Alergol Pol. 2008;76:281-285.
  • 16
    Calabro L, Di Giacomo AM, Altomonte M, et al. Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? J Exp Clin Cancer Res. 2007;26:145-150.
  • 17
    Mascarenhas RC, Sanghvi AN, Friedlander L, et al. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology. 2004;67:471-475.
  • 18
    Raphael C, Hudson E, Williams L, Lester JF, Savage PM. Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thamidomide: a case report [serial online]. J Med Case Rep. 2010;4:413.
  • 19
    Salech F, Valderrama S, Nervi B, et al. Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. Ann Hepatol. 2011;10:99-102.
  • 20
    Trautmann K, Bethke A, Ehninger G, Folprecht G. Bevacizumab for recurrent hemangioendothelioma. Acta Oncol. 2011;50:153-154.
  • 21
    Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257-263.
  • 22
    Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial. Invest New Drugs. 2011;29:481-488.
  • 23
    Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002;20:4478-4484.